BRAF Primary Antibody
|Aliases||BRAF1; RAFB1; B-RAF1; FLJ95109|
|Formulation||Ascitic fluid containing 0.03% sodium azide.|
|Immunogen||Purified recombinant fragment of human BRAF expressed in E. Coli. |
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|Species Reactivity||Human, Mouse|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|WB (Western Blot)||1/500 - 1/2000|
BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1; RAFB1; B-RAF1; FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.
|References (references)||1. J Clin Oncol. 2008 Dec 10;26(35):5705-12. |
2. Endocr Relat Cancer. 2006 Mar;13(1):257-69.